{
  "main_header": {
    "sid": 1158024,
    "name": "NeoGenomics, Inc.",
    "stock_name": "NeoGenomics, Inc.",
    "full_name": "NeoGenomics, Inc.",
    "name_url": "stocks-analysis/neogenomics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "11.90",
    "chg": -0.27,
    "chgp": "-2.22%",
    "dir": -1,
    "prev_price": "12.17",
    "mcapval": "1,024.39",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US64049M2098",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.8 M",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/neogenomics-inc-1158024-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neogenomics-inc-technical-trend-shifts-from-mildly-bearish-to-sideways-amid-stock-volatility-3640413",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NeoGenomicsInc_technicaldot_3640413.png",
        "date": "2025-10-20 15:19:10",
        "description": "NeoGenomics, Inc. has recently revised its evaluation amid market fluctuations, with a stock price of $10.28. The company has experienced notable short-term returns but faces challenges over the longer term, as indicated by its year-to-date performance and historical returns compared to the S&P 500."
      },
      {
        "title": "Is NeoGenomics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-neogenomics-inc-technically-bullish-or-bearish-3546851",
        "imagepath": "",
        "date": "2025-09-20 19:41:47",
        "description": "As of 26 August 2025, the technical trend for NeoGenomics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment, while the weekly MACD and KST show a mildly bullish outlook. However, the monthly indicators remain predominantly bearish. The stock has outperformed the S&P 500 over the past week and month, returning 3.36% and 38.14% respectively, but it has significantly underperformed over longer periods, with a year-to-date return of -47.69% compared to the S&P 500's 12.22%...."
      },
      {
        "title": "Is NeoGenomics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-neogenomics-inc-overvalued-or-undervalued-3543339",
        "imagepath": "",
        "date": "2025-09-20 18:16:46",
        "description": "As of 25 February 2022, the valuation grade for NeoGenomics, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of 1.07, an EV to EBIT of -14.14, and an EV to EBITDA of -131.00. Comparatively, peers such as The Ensign Group, Inc. have a P/E ratio of 32.46 and an EV to EBITDA of 21.10, showcasing a stark contrast in valuation metrics.\n\nAdditionally, NeoGenomics has underperformed significantly relative to the S&P 500, with a year-to-date return of -47.69% compared to the index's 12.22%. This underperformance, coupled with the company's negative returns over multiple periods, further reinforces the assessment that NeoGenomics is overvalued in its current state...."
      }
    ],
    "total": 8,
    "sid": "1158024",
    "stock_news_url": "https://www.marketsmojo.com/news/neogenomics-inc-1158024"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations

2025-10-20 15:19:10

NeoGenomics, Inc. has recently revised its evaluation amid market fluctuations, with a stock price of $10.28. The company has experienced notable short-term returns but faces challenges over the longer term, as indicated by its year-to-date performance and historical returns compared to the S&P 500.

Read More

Is NeoGenomics, Inc. technically bullish or bearish?

2025-09-20 19:41:47

As of 26 August 2025, the technical trend for NeoGenomics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment, while the weekly MACD and KST show a mildly bullish outlook. However, the monthly indicators remain predominantly bearish. The stock has outperformed the S&P 500 over the past week and month, returning 3.36% and 38.14% respectively, but it has significantly underperformed over longer periods, with a year-to-date return of -47.69% compared to the S&P 500's 12.22%....

Read More

Is NeoGenomics, Inc. overvalued or undervalued?

2025-09-20 18:16:46

As of 25 February 2022, the valuation grade for NeoGenomics, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of 1.07, an EV to EBIT of -14.14, and an EV to EBITDA of -131.00. Comparatively, peers such as The Ensign Group, Inc. have a P/E ratio of 32.46 and an EV to EBITDA of 21.10, showcasing a stark contrast in valuation metrics. Additionally, NeoGenomics has underperformed significantly relative to the S&P 500, with a year-to-date return of -47.69% compared to the index's 12.22%. This underperformance, coupled with the company's negative returns over multiple periods, further reinforces the assessment that NeoGenomics is overvalued in its current state....

Read More

View All News